Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Sponsor: Iovance Biotherapeutics, Inc.

Expanded Access
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05398640

Patient View

This open-label, multi-center program evaluates lifileucel, an autologous TIL therapy, for advanced melanoma. Patients undergo tumor resection for TIL generation, followed by NMA-LD, TIL infusion, and high-dose IL-2. Eligible participants are adults with unresectable/metastatic melanoma, ECOG 0-1, and no alternative therapy. Exclusions include prior cell therapy and active brain metastases.

Patient Parameters

Program Overview

The objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.

Description

This program provides access to OOS AMTAGVI (lifileucel) that does not meet commercial release criteria but does meet Iovance clinical trial release criteria. Patients will be followed for safety and efficacy.

Eligibility Criteria

Inclusion Criteria

  1. Eligible for treatment with AMTAGVI per United States Prescribing Information (USPI)
  2. Have an AMTAGVI product manufactured for commercial treatment; however, the final manufactured product did not meet commercial release criteria but was deemed safe and acceptable for release after risk/benefit assessment
  3. Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and for 12 months after receiving the last protocol-related therapy

Exclusion Criteria

  1. History of hypersensitivity to cyclophosphamide, mesna, fludarabine, or any component of lifileucel cryopreservation medium
  2. Ongoing systemic infection
  3. Cardiopulmonary or renal disorder which may make patient ineligible for treatment with cyclophosphamide, fludarabine or IL-2, at the discretion of the Treating Physician
  4. Experience a significant worsening in clinical status that would, in the opinion of the Treating Physician, increase the risk of toxicities from treatment with lymphodepleting chemotherapy, AMTAGVI product that is out of specification, or IL-2
  5. Any other condition, laboratory abnormality and/or pre-treatment assessment that places patient at unacceptable risk if they were to participate in the EAP based on the Treating Physician's judgment
  6. Pregnant or breastfeeding

Get This Program In Your Inbox

You can sign up and apply your patients for this program.